• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

7 Myths About Cholesterol, Debunked
You may not recall every lab value from your last physical, but you probably remember one: Your cholesterol level. If it’s higher than ideal, you’re not alone. According to the U.S. Centers for Disease Control and Prevention, between 2015 and 2018, almost 12% of U.S. adults ages 20 and up had high total cholesterol, defined as above 240 mg/dL. The type that physicians mostly worry about is LDL (or “bad”) cholesterol, which is one component of that total. Why do doctors care so much about cholesterol? First, “it predicts risk,” says Dr. Jeffrey Berger, a cardiologist and director of the C...
Source: TIME: Health - June 19, 2023 Category: Consumer Health News Authors: Katherine Hobson Tags: Uncategorized freelance healthscienceclimate heart health Source Type: news

Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome
This study was a prospective, randomized controlled study. A total of 136 patients with extremely high-risk ACS with LDL-C ≥ 3.0 mmol/L after percutaneous coronary intervention (PCI) treatment were randomly assigned 1:1 to the control group (atorvastatin 40 mg/day and ezetimibe 10 mg/day) or the evolocumab group (evolocumab 140 mg every 2 weeks combined with atorvastatin 40 mg/day and ezetimibe 10 mg/day). We compared the blood lipid profiles, major adverse cardiovascular events (MACEs), and adverse reactions. MACEs included cardiogenic death, nonfatal myocardial infarction, nonfatal stroke, and readmission due to angina...
Source: International Heart Journal - July 13, 2022 Category: Cardiology Authors: Yan Hao Yu-Lin Yang Yong-Chao Wang Jian Li Source Type: research

Prevalence of and Factors Associated With the Prescription of Fibrates Among Patients Receiving Lipid-Lowering Drugs in Germany
Abstract: Little recent data are available about the patterns of prescription for fibrates in patients followed in primary care practices. Therefore, the goal of this study was to analyze the prevalence of and the factors associated with the use of fibrates among patients receiving lipid-lowering drugs in Germany. The study included patients aged ≥18 years with at least 1 visit to 1 of 1070 general practices in Germany between January and December 2019. Lipid-lowering drugs included statins (without and with ezetimibe) and fibrates. The prevalence of the prescription of fibrates corresponded to the number of patients...
Source: Journal of Cardiovascular Pharmacology - December 1, 2021 Category: Cardiology Tags: Original Article Source Type: research

Bempedoic acid: a cholesterol lowering agent with a novel mechanism of action
Expert Rev Clin Pharmacol. 2021 Mar 11. doi: 10.1080/17512433.2021.1901579. Online ahead of print.ABSTRACTINTRODUCTION: Dyslipidemia is a common condition that increases the risk of heart diseases and stroke. High levels of low-density lipoprotein-cholesterol (LDL-C) is correlated with a higher risk for heart disease. A drug class known as "statins" is the gold standard for LDL-C-lowering, but its use in some patients is limited by its adverse effects of myalgias and myopathies. Use of other LDL-C-lowering agents are frequently limited by cost and degree of efficacy. Additionally, many high-risk atherosclerotic cardiovascu...
Source: Expert Review of Clinical Pharmacology - March 11, 2021 Category: Drugs & Pharmacology Authors: Huyen Nguyen Ikenna Akamnonu Tianrui Yang Source Type: research

Pages: 1  2  3